CA3213395A1 - Compositions and methods for treating polycythemia - Google Patents
Compositions and methods for treating polycythemia Download PDFInfo
- Publication number
- CA3213395A1 CA3213395A1 CA3213395A CA3213395A CA3213395A1 CA 3213395 A1 CA3213395 A1 CA 3213395A1 CA 3213395 A CA3213395 A CA 3213395A CA 3213395 A CA3213395 A CA 3213395A CA 3213395 A1 CA3213395 A1 CA 3213395A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- polycythemia
- group
- inhibitor
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160412P | 2021-03-12 | 2021-03-12 | |
| US63/160,412 | 2021-03-12 | ||
| US202163185464P | 2021-05-07 | 2021-05-07 | |
| US63/185,464 | 2021-05-07 | ||
| PCT/US2022/020038 WO2022192730A1 (en) | 2021-03-12 | 2022-03-11 | Compositions and methods for treating polycythemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3213395A1 true CA3213395A1 (en) | 2022-09-15 |
Family
ID=83228388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3213395A Pending CA3213395A1 (en) | 2021-03-12 | 2022-03-11 | Compositions and methods for treating polycythemia |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20260027107A1 (https=) |
| EP (1) | EP4304596A4 (https=) |
| JP (1) | JP2024509265A (https=) |
| KR (1) | KR20230169981A (https=) |
| AU (1) | AU2022233178A1 (https=) |
| BR (1) | BR112023018403A2 (https=) |
| CA (1) | CA3213395A1 (https=) |
| IL (1) | IL305806A (https=) |
| MX (1) | MX2023010449A (https=) |
| WO (1) | WO2022192730A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230169981A (ko) * | 2021-03-12 | 2023-12-18 | 디스크 메디슨, 인크. | 적혈구증가증을 치료하기 위한 조성물 및 방법 |
| CN116942668A (zh) * | 2023-03-17 | 2023-10-27 | 天津医科大学 | Glyt1抑制剂在治疗器官纤维化中的应用 |
| AU2024339974A1 (en) * | 2023-09-15 | 2026-03-26 | Disc Medicine, Inc. | Glyt-1 inhibitors and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20180036A1 (ar) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| KR20230169981A (ko) * | 2021-03-12 | 2023-12-18 | 디스크 메디슨, 인크. | 적혈구증가증을 치료하기 위한 조성물 및 방법 |
-
2022
- 2022-03-11 KR KR1020237034671A patent/KR20230169981A/ko active Pending
- 2022-03-11 MX MX2023010449A patent/MX2023010449A/es unknown
- 2022-03-11 BR BR112023018403A patent/BR112023018403A2/pt unknown
- 2022-03-11 WO PCT/US2022/020038 patent/WO2022192730A1/en not_active Ceased
- 2022-03-11 AU AU2022233178A patent/AU2022233178A1/en active Pending
- 2022-03-11 US US18/280,837 patent/US20260027107A1/en active Pending
- 2022-03-11 EP EP22768132.7A patent/EP4304596A4/en active Pending
- 2022-03-11 IL IL305806A patent/IL305806A/en unknown
- 2022-03-11 JP JP2023555275A patent/JP2024509265A/ja active Pending
- 2022-03-11 CA CA3213395A patent/CA3213395A1/en active Pending
-
2024
- 2024-03-05 US US18/596,341 patent/US20240269132A1/en not_active Abandoned
- 2024-10-23 US US18/923,904 patent/US20250248995A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240269132A1 (en) | 2024-08-15 |
| US20260027107A1 (en) | 2026-01-29 |
| US20250248995A1 (en) | 2025-08-07 |
| MX2023010449A (es) | 2023-11-09 |
| WO2022192730A1 (en) | 2022-09-15 |
| KR20230169981A (ko) | 2023-12-18 |
| JP2024509265A (ja) | 2024-02-29 |
| EP4304596A1 (en) | 2024-01-17 |
| IL305806A (en) | 2023-11-01 |
| AU2022233178A1 (en) | 2023-10-26 |
| EP4304596A4 (en) | 2025-02-19 |
| BR112023018403A2 (pt) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3213395A1 (en) | Compositions and methods for treating polycythemia | |
| US20250262204A1 (en) | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | |
| BR112019016775A2 (pt) | Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos | |
| US20240325382A1 (en) | Compositions and methods for treating anemia associated with a ribosomal disorder | |
| CA3220137A1 (en) | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | |
| US20250302823A1 (en) | Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors | |
| HK40105387A (zh) | 用於治疗红细胞增多症的组合物和方法 | |
| CN118319913A (zh) | 用于治疗红细胞增多症的组合物和方法 | |
| HK40112808A (zh) | 用於治疗与核糖体障碍相关的贫血的组合物和方法 | |
| HK40105830A (zh) | 用於治疗与核糖体障碍相关的贫血的组合物和方法 | |
| WO2026064696A1 (en) | Compositions and methods for treating myelodysplastic syndrome with glycine transport inhibitors | |
| CN118319914A (zh) | 用于治疗与核糖体障碍相关的贫血的组合物和方法 | |
| HK40123243A (zh) | 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法 | |
| HK40082113A (en) | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250226 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260224 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260311 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260311 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260311 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260323 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260323 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260323 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260324 |